Session » (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1568

A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level

10:30AM-12:30PM: Abstract Number: 1574

A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1559

Anti-Cytolethal Distending Toxin Antibodies in Systemic Sclerosis: Associations with Gastrointestinal Disease and Immune Dysregulation

10:30AM-12:30PM: Abstract Number: 1557

Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1590

Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients

10:30AM-12:30PM: Abstract Number: 1565

Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study

10:30AM-12:30PM: Abstract Number: 1569

Can We Use Patient Reported Outcomes For Home-monitoring in SSc?

10:30AM-12:30PM: Abstract Number: 1553

Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1575

Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.

10:30AM-12:30PM: Abstract Number: 1572

Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis

10:30AM-12:30PM: Abstract Number: 1567

Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1554

Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis

10:30AM-12:30PM: Abstract Number: 1583

Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021

10:30AM-12:30PM: Abstract Number: 1584

Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics

10:30AM-12:30PM: Abstract Number: 1579

Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1566

Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1558

Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study

10:30AM-12:30PM: Abstract Number: 1573

Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival

10:30AM-12:30PM: Abstract Number: 1570

Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses

10:30AM-12:30PM: Abstract Number: 1576

Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study

10:30AM-12:30PM: Abstract Number: 1577

Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).

10:30AM-12:30PM: Abstract Number: 1556

Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time

10:30AM-12:30PM: Abstract Number: 1560

Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1587

Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains

10:30AM-12:30PM: Abstract Number: 1580

Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis

10:30AM-12:30PM: Abstract Number: 1589

Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation

10:30AM-12:30PM: Abstract Number: 1591

Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis

10:30AM-12:30PM: Abstract Number: 1588

Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study

10:30AM-12:30PM: Abstract Number: 1555

Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database

10:30AM-12:30PM: Abstract Number: 1586

Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study

10:30AM-12:30PM: Abstract Number: 1563

RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1582

Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)

10:30AM-12:30PM: Abstract Number: 1571

Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling

10:30AM-12:30PM: Abstract Number: 1581

The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 1578

Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series

10:30AM-12:30PM: Abstract Number: 1561

Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion

10:30AM-12:30PM: Abstract Number: 1564

Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1562

Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].